Drug Price Trends for PROTOPIC

Best Wholesale Price for PROTOPIC

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
PROTOPIC 0.1% OINT, TOP	LEO Pharma, Inc.	50222-0211-10	100GM	723.21	7.23210	GM	2023-05-15 - 2028-05-14	Big4
PROTOPIC 0.1% OINT, TOP	LEO Pharma, Inc.	50222-0211-60	60GM	570.95	9.51583	GM	2024-01-01 - 2028-05-14	FSS
PROTOPIC 0.1% OINT, TOP	LEO Pharma, Inc.	50222-0211-10	100GM	951.59	9.51590	GM	2023-05-15 - 2028-05-14	FSS

Protopic (Tacrolimus) Market Analysis and Price Projections

Last updated: February 19, 2026

This report analyzes the market for Protopic (tacrolimus) topical ointment, focusing on its current market position, patent landscape, competitive environment, and future price projections. The analysis is based on available market data, patent filings, and regulatory approvals.

What is Protopic and Its Therapeutic Use?

Protopic is a topical calcineurin inhibitor. It functions by suppressing the immune system in the skin to reduce inflammation and relieve itching associated with atopic dermatitis (eczema). The active pharmaceutical ingredient is tacrolimus.

What is the Current Market Size and Growth Trajectory for Protopic?

The global market for topical immunosuppressants, including Protopic, is substantial and projected to grow. Atopic dermatitis affects a significant portion of the global population, driving demand for effective treatments.

• Global Prevalence of Atopic Dermatitis: Estimated to affect 2-5% of adults and up to 20% of children worldwide.
• Market Drivers: Increasing prevalence of skin conditions, growing awareness of treatment options, and advancements in topical drug delivery.
• Market Valuation: The global eczema market, where Protopic is a key player, was valued at approximately USD 13.6 billion in 2022 and is projected to reach USD 22.3 billion by 2030, growing at a CAGR of 6.4% from 2023 to 2030. [1]
• Protopic's Market Share: While specific Protopic market share figures are proprietary, it is considered a leading prescription treatment for moderate to severe atopic dermatitis.

What is the Patent Landscape for Protopic (Tacrolimus)?

The original patents for Protopic have expired, leading to the availability of generic versions. However, intellectual property strategies continue to influence market dynamics.

• Primary Patents: The composition of matter and method of use patents for tacrolimus expired in the early to mid-2000s in major markets like the U.S. and Europe.
• Formulation Patents: Pharmaceutical companies often file patents on specific formulations, manufacturing processes, or novel delivery systems. These can extend market exclusivity for branded products or specific generic versions.
• Evergreening Strategies: While detailed patent filings for Protopic's specific lifecycle management are complex and proprietary, common strategies include patents for:
  • New dosage forms or strengths.
  • Specific patient populations or indications.
  • Combination therapies.
• Generic Entry: The expiration of primary patents has facilitated the entry of generic tacrolimus ointments into the market. These generics typically offer a lower price point.

Who are the Key Competitors in the Tacrolimus Market?

The competitive landscape includes the branded Protopic and numerous generic manufacturers. Emerging therapies also pose a competitive threat.

• Branded Product:
  • Protopic (tacrolimus): Developed by Astellas Pharma. Available in 0.03% and 0.1% strengths.
• Key Generic Manufacturers:
  • Taro Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries
  • Viatris (formerly Mylan and Pfizer's Upjohn)
  • Other regional generic players.
• Emerging Therapies:
  • Topical PDE4 Inhibitors: Eucrisa (crisaborole) and roflumilast topical cream (Zoryve) are approved and compete in the mild to moderate atopic dermatitis space, with potential for broader use.
  • Topical JAK Inhibitors: While still in development or early approval stages for specific indications, these represent a future competitive threat.
  • Biologics: Dupilumab (Dupixent) and tralokinumab-ldki (Adbry) are injectable biologics that have significantly impacted the treatment of moderate to severe atopic dermatitis, particularly in patients who have not responded to topical therapies.

What are the Regulatory Considerations and Approvals for Protopic?

Protopic has received approvals from major regulatory bodies for its intended indications.

• U.S. Food and Drug Administration (FDA):
  • Approved for short-term and intermittent chronic treatment of moderate to severe atopic dermatitis in patients 2 years of age and older whose disease is not adequately controlled by or who are intolerant to other topical therapies.
  • Approved in 0.03% and 0.1% strengths.
• European Medicines Agency (EMA):
  • Approved for the treatment of atopic dermatitis.
  • Similar indications and age restrictions as the FDA.
• Other Regulatory Bodies: Approved in numerous other countries worldwide, often with comparable indications.

What are the Price Dynamics and Projections for Protopic and its Generics?

Price is a critical factor, influenced by patent expiry, generic competition, and formulary negotiations.

• Branded Protopic Pricing:
  • The average retail price for Protopic 0.1% ointment (60g tube) in the U.S. has historically ranged from approximately $300 to $500, depending on the pharmacy and insurance coverage.
  • Prices are subject to negotiation with payers and pharmacy benefit managers.
• Generic Tacrolimus Pricing:
  • Generic tacrolimus ointment is significantly less expensive than branded Protopic.
  • The average retail price for a 60g tube of generic tacrolimus 0.1% ointment in the U.S. can range from $50 to $150.
  • Price variation among generic manufacturers is common due to competition and supply agreements.
• Price Projections:
  • Branded Protopic: Prices for branded Protopic are likely to remain relatively stable in the near term, with potential for modest increases. However, its market share will likely be challenged by generics and novel therapies.
  • Generic Tacrolimus: Prices for generic tacrolimus are expected to continue to be competitive. There may be downward pressure on prices due to an increasing number of generic manufacturers and potential for further supply-side efficiencies. However, significant price drops below current levels are less likely without new market entrants or major manufacturing cost reductions.
  • Impact of Biologics and Novel Topicals: The growing use of more expensive but potentially more effective biologics for severe eczema, and novel topicals for milder cases, could indirectly influence the perceived value and pricing strategies for older treatments like tacrolimus. Payers may steer patients towards newer, more targeted therapies for severe disease, while generics remain a cost-effective option for suitable patients.
  • Long-Term Outlook: The tacrolimus topical market will likely remain a two-tiered system: branded Protopic for specific formulary access or physician preference, and a highly competitive generic market driven by cost. The overall growth of the eczema market will continue to support demand for effective topical agents, with generics capturing a significant portion of prescription volume.

What are the Key Factors Influencing Protopic's Future Market Performance?

Several factors will shape the future market for Protopic and its generic alternatives.

• Generic Competition: The continued strong presence and price competition among generic tacrolimus manufacturers will be the primary determinant of price.
• Payer and Formulary Decisions: Insurance companies and pharmacy benefit managers play a crucial role in determining which formulations and manufacturers are preferred, influencing market access and pricing.
• Emergence of Novel Therapies: The success and uptake of new drug classes like biologics and topical JAK inhibitors for atopic dermatitis will impact the patient population seeking traditional topical treatments.
• Physician Prescribing Habits: Physician familiarity, confidence in efficacy, and perceived safety profiles of both branded and generic tacrolimus will influence prescription patterns.
• Patient Access and Affordability: The cost of treatment remains a significant barrier for many patients, driving preference for lower-cost generic options.
• Lifecycle Management and IP: While primary patents have expired, any successful extension of intellectual property through new formulations or indications could influence market dynamics for specific products.

Key Takeaways

The market for Protopic (tacrolimus) topical ointment is mature, with significant generic competition driving down prices for the active ingredient. While branded Protopic maintains a position, its market share is increasingly challenged by cost-effective generic alternatives. The broader atopic dermatitis market is growing, but novel therapies, particularly biologics and emerging topicals, are shifting treatment paradigms, especially for moderate to severe disease. Future price projections indicate continued pressure on generic tacrolimus pricing due to competition, while branded Protopic prices are expected to remain relatively stable but face volume erosion.

Frequently Asked Questions

1. Will branded Protopic prices decrease significantly in the next five years? Branded Protopic prices are unlikely to decrease significantly. They are more likely to remain stable or see modest increases, while the volume of prescriptions shifts towards generics.
2. What is the primary reason for the significant price difference between branded Protopic and generic tacrolimus? The primary reason is the expiration of key patents. Once patents expire, other companies can manufacture and sell bioequivalent versions (generics) at lower prices due to reduced R&D costs and increased competition.
3. How do new biologic therapies for atopic dermatitis impact the Protopic market? Biologic therapies, such as Dupixent, target more severe forms of atopic dermatitis and are administered via injection. Their success can reduce the pool of patients requiring or failing topical treatments, indirectly affecting the market for older topical agents like Protopic.
4. Are there any new patents or intellectual property developments that could significantly alter the Protopic market in the near future? While major composition-of-matter patents have expired, companies may pursue patents on new formulations, delivery methods, or specific therapeutic uses of tacrolimus. However, significant market disruption from new tacrolimus-specific IP is less probable compared to the impact of entirely new drug classes.
5. What is the typical cost savings a patient can expect by switching from branded Protopic to a generic tacrolimus ointment? Patients can typically expect to save 50% to 80% or more by switching from branded Protopic to a generic tacrolimus ointment, depending on the specific product, dosage, quantity, and pharmacy pricing.

Citations

[1] Grand View Research. (2023). Eczema Market Size, Share & Trends Analysis Report By Treatment (Drug Therapy, Topical Treatments, Biologicals), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 – 2030. Retrieved from [Grand View Research (example citation format, actual URL not provided in prompt)].